Entering text into the input field will update the search result below

Aveo Pharma set to continue tivozanib-stoked up move; shares up 31% premarket

  • Micro cap Aveo Pharmaceuticals (NASDAQ:AVEO) is up 31% premarket on robust volume as investors continue to pile in after a presentation at ASCO two days ago of positive data on its lead product candidate, tivozanib, in kidney cancer.
  • Shares have almost tripled since mid-May.
  • Previously: Aveo up on positive tivozanib data; shares up 17% premarket (June 2)

Recommended For You

Related Stocks

SymbolLast Price% Chg
AVEO--
AVEO Pharmaceuticals, Inc.